GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ganga Pharmaceuticals Ltd (BOM:539680) » Definitions » EBIT

Ganga Pharmaceuticals (BOM:539680) EBIT : ₹2.89 Mil (TTM As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Ganga Pharmaceuticals EBIT?

Ganga Pharmaceuticals's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2024 was ₹1.57 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹2.89 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Ganga Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2024 was -1.16%. Ganga Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 6.76%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Ganga Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 2.86%.


Ganga Pharmaceuticals EBIT Historical Data

The historical data trend for Ganga Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ganga Pharmaceuticals EBIT Chart

Ganga Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.73 2.17 2.42 2.40 2.44

Ganga Pharmaceuticals Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.67 0.73 1.13 1.32 1.57

Competitive Comparison of Ganga Pharmaceuticals's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Ganga Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ganga Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ganga Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ganga Pharmaceuticals's EV-to-EBIT falls into.



Ganga Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹2.89 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ganga Pharmaceuticals  (BOM:539680) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Ganga Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-2.724 * ( 1 - 64.29% )/( (84.674 + 83.163)/ 2 )
=-0.9727404/83.9185
=-1.16 %

where

Note: The Operating Income data used here is two times the semi-annual (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Ganga Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=3.134/( ( (6.125 + max(38.982, 0)) + (5.964 + max(41.583, 0)) )/ 2 )
=3.134/( ( 45.107 + 47.547 )/ 2 )
=3.134/46.327
=6.76 %

where Working Capital is:

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.232 + 12.413 + 19.659) - (1.504 + 0 + 0.818)
=38.982

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.991 + 11.727 + 23.504) - (2.179 + 0 + 1.46)
=41.583

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Ganga Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=2.885/100.904
=2.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ganga Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Ganga Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Ganga Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Dhanvantri Marg, Gangatat, Gopcharpada, Near Digi 1 Electronic Showroom, Virar (East), Palghar, MH, IND, 401305
Ganga Pharmaceuticals Ltd is an India based producer of ayurvedic medicines. It is engaged in the business of manufacturing and trading in ayurvedic pharmaceuticals and allied products. The company is also involved in the marketing and distribution of bulk ayurvedic medicines. The firm offers ayurvedic medicines for acidity, anti-dandruff, anti-oxidants, dental care, diarrhea, iron tonic, liver disorder, weight management, kidney stone, joint pains, liver disorder and others.

Ganga Pharmaceuticals Headlines

No Headlines